Intravesical treatments of bladder cancer: Review

Pharmaceutical Research

Volumn 25, Issue 7, 2008, Pages 1500-1510

  Shen, Zancong ^a   Shen, Tong ^a   Wientjes, M Guillaume ^a,b   O'Donnell, Michael A ^c   Au, Jessie L S ^a,b  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c UNIVERSITY OF IOWA   (United States)

Author keywords

Bladder cancer; Computational modeling; Intravesical therapy; Pharmacokinetic pharmacodynamic; Regional therapy

Indexed keywords

ADENOVIRUS VECTOR; ALPHA INTERFERON; ALPHA2B INTERFERON; BASIC FIBROBLAST GROWTH FACTOR; BCG VACCINE; CHITOSAN; CISPLATIN; DIMETHYL SULFOXIDE; DOXORUBICIN; EPIRUBICIN; FLUOROURIDINE; GEMCITABINE; HYALURONIDASE; INTERLEUKIN 12; INTERLEUKIN 8; LIPOPLEX; MITOMYCIN C; MOXIFLOXACIN; PACLITAXEL; PIPEMIDIC ACID; PIRARUBICIN; POLYCARBOPHIL; PROTEIN P53; SMALL INTERFERING RNA; SURAMIN; SURVIVIN; THIOTEPA; UNINDEXED DRUG; VALRUBICIN; VIRUS VECTOR;

BLADDER CANCER; BLADDER WALL; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER PREVENTION; CANCER RECURRENCE; CANCER RESISTANCE; CANCER SURVIVAL; CARCINOMA IN SITU; COMPUTER SIMULATION; DISEASE FREE SURVIVAL; DRUG DISPOSITION; DRUG TREATMENT FAILURE; DRUG URINE LEVEL; GENETIC TRANSFECTION; HUMAN; HYPERTHERMIC THERAPY; IMMUNOGENICITY; INTERSTITIAL CYSTITIS; IONTOPHORESIS; LIPOSOMAL GENE DELIVERY SYSTEM; MONOLAYER CULTURE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NONVIRAL GENE THERAPY; PRIORITY JOURNAL; REVIEW; SURVIVAL RATE; SURVIVAL TIME; THERAPY EFFECT; TRANSGENE; TRANSITIONAL CELL CARCINOMA; TREATMENT OUTCOME; TREATMENT RESPONSE; VACCINIA VIRUS; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VITREOUS HEMORRHAGE;

ALGORITHMS; ANIMALS; ANTINEOPLASTIC AGENTS; COMPUTER SIMULATION; HUMANS; URINARY BLADDER NEOPLASMS;

EID: 44749093232     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-008-9566-7     Document Type: Review

References (154)

1. American Cancer Society. Cancer facts and figures. American Cancer Society, Atlanta, GA, 2007.
2. E. A. Schenk-Braat, and C.H. Bangma. Immunotherapy for superficial bladder cancer. Cancer Immunol. Immunother. 54:414-423 (2005).
3. E. A. De Bruijn, H. P. Sleeboom, P. J. van Helsdingen, A. T. van Oosterom, U. R. Tjaden, and R. A. Maes. Pharmacodynamics and pharmacokinetics of intravesical mitomycin C upon different dwelling times. Int. J. Cancer. 51:359-364 (1992).
4. M. Chai, M. G. Wientjes, R. A. Badalament, J. K. Burgers, and J. L. Au. Pharmacokinetics of intravesical doxorubicin in superficial bladder cancer patients. J. Urol. 152:374-378 (1994).
5. D. Song, M. G. Wientjes, and J. L. Au. Bladder tissue pharmacokinetics of intravesical taxol. Cancer Chemother. Pharmacol. 40:285-292 (1997).
6. U. Engelmann, H. J. Knopf, and J. Graff. Interferon-alpha 2b instillation prophylaxis in superficial bladder cancer-a prospective, controlled three-armed trial. Project Group Bochum-Interferon and Superficial Bladder Cancer. Anti-cancer Drugs. 3(Suppl 1):33-37 (1992).
7. N. E. Stavropoulos, K. Hastazeris, I. Filiadis, I. Mihailidis, E. Ioachim, Z. Liamis et al. Intravesical instillations of interferon gamma in the prophylaxis of high risk superficial bladder cancer-results of a controlled prospective study. Scand. J. Urol. Nephrol. 36:218-222 (2002).
8. F. N. Joudi, B. J. Smith, and M. A. O'Donnell. Final results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer. Urol. Oncol. 24:344-348 (2006).
9. A. M. Nouri, R. Hyde, and R. T. Oliver. Clinical and immunological effect of intravesical interleukin-2 on superficial bladder cancer. Cancer Immunol. Immunother. 39:68-70 (1994).
10. G. Ferlazzo, C. Magno, R. Iemmo, M. Rizzo, G. Lupo, C. Semino et al. Treatment of superficial bladder cancer with intravesical perfusion of rIL-2: a follow-up study. Anticancer Res. 16:979-980 (1996).
11. C. Magno, D. Melloni, A. Gali, G. Mucciardi, G. Nicocia, B. Morandi et al. The anti-tumor activity of bacillus Calmette-Guerin in bladder cancer is associated with an increase in the circulating level of interleukin-2. Immunol. Lett. 81:235-238 (2002).
12. S. K. Clinton, E. Canto, and M. A. O'Donnell. Interleukin-12. Opportunities for the treatment of bladder cancer. Urol. Clin. North Am. 27:147-155 (2000).
13. G. R. Weiss, M. A. O'Donnell, K. Loughlin, K. Zonno, R. J. Laliberte, and M. L. Sherman. Phase 1 study of the intravesical administration of recombinant human interleukin-12 in patients with recurrent superficial transitional cell carcinoma of the bladder. J. Immunother. (1997). 26:343-348 (2003).
14. V. Serretta, G. Corselli, B. Piazza, C. R. Franks, P. A. Palmer, G. J. Roest et al. Intravesical therapy of superficial bladder transitional cell carcinoma with tumor necrosis factor-alpha: preliminary report of a phase I-II study. Eur. Urol. 22:112-114 (1992).
15. V. Serretta, B. Piazza, C. Pavone, S. Piazza, and M. Pavone-Macaluso. Is there a role for recombinant tumor necrosis factor alpha in the intravesical treatment of superficial bladder tumors?-a phase II study. Int. J. Urol. 2:100-103 (1995).
16. D. B. Glazier, R. R. Bahnson, D. G. McLeod, R. W. von Roemeling, E. M. Messing, and M.S. Ernstoff. Intravesical recombinant tumor necrosis factor in the treatment of superficial bladder cancer: an Eastern Cooperative Oncology Group study. J. Urol. 154:66-68 (1995).
17. M. M. Wishahi, I. M. Ismail, H. Ruebben, and T. Otto. Keyhole-limpet hemocyanin immunotherapy in the bilharzial bladder: a new treatment modality? Phase II trial: superficial bladder cancer. J. Urol. 153:926-928 (1995).
18. C. D. Jurincic-Winkler, K. A. Metz, J. Beuth, and K. F. Klippel. Keyhole limpet hemocyanin for carcinoma in situ of the bladder: a long-term follow-up study. Eur. Urol. 37(Suppl 3):45-49 (2000).
19. T. M. de Reijke, E. C. de Boer, D. H. Schamhart, and K. H. Kurth. Immunostimulation in the urinary bladder by local application of Nocardia rubra cell wall skeleton preparation (Rubratin) for superficial bladder cancer immunotherapy-a phase I/II study. Urol. Res. 25:117-120 (1997).
20. E. C. de Boer, T. M. De Reijke, P. C. Vos, K. H. Kurth, and D. H. Schamhart. Immunostimulation in the urinary bladder by local application of Nocardia rubra cell-wall skeletons (Rubratin) and bacillus Calmette-Guerin as therapy for superficial bladder cancer: a comparative study. Clin. Infect. Dis. 31(Suppl 3):S109-S114 (2000).
21. A. Allona Moncada, S. Garcia Vaquero, A. Zuloaga Gomez, J. L. Martinez Torres, R. Lopez-Pardo, J. Molina et al. Preliminary results of a multicenter study with mitomycin C in superficial bladder tumors (Ta, T1). Actas Urol. Esp. 12:424-429 (1988).
22. A. P. van der Meijden, and F. M. DeBruyne. Treatment schedule of intravesical chemotherapy with mitomycin C in superficial bladder cancer: short-term courses or maintenance therapy. Urology. 31(Suppl 3):26-29 (1988).
23. R. Colombo, A. Lev, L. F. Da Pozzo, M. Freschi, G. Gallus, and P. Rigatti. A new approach using local combined microwave hyperthermia and chemotherapy in superficial transitional bladder carcinoma treatment. J. Urol. 153:959-963 (1995).
24. J. Kondas, L. Kiss, A. Hatar, A. Kiss, T. Lukacs, P. Szeldeli et al. The effect of intravesical mitomycin C on the recurrence of superficial (Ta-T1) bladder cancer. A Hungarian Multicenter Study. Int. Urol. Nephrol. 31:451-456 (1999).
25. S. M. Di Stasi, A. Giannantoni, R. L. Stephen, G. Capelli, P. Navarra, R. Massoud et al. Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study. J. Urol. 170:777-782 (2003).
26. K. Obata, Y. Ohashi, H. Akaza, S. Isaka, S. Kagawa, K. Koiso et al. Prophylactic chemotherapy with intravesical instillation of adriamycin and oral administration of 5-fluorouracil after surgery for superficial bladder cancer. The Japanese Urological Cancer Research Group for Adriamycin. Cancer Chemother. Pharmacol. 35:S88-S92 (1994).
27. K. Ueda, H. Sakagami, Y. Masui, and T. Okamura. Single instillation of hydroxypropylcellulose-doxorubicin as treatment for superficial bladder carcinoma. Cancer Chemother. Pharmacol. 35:S81-83 (1994).
28. S. Hinotsu, H. Akaza, S. Isaka, S. Kagawa, K. Koiso, T. Kotake et al. Intravesical instillation of doxorubicin or epirubicin for chemoprophylaxis of superficial bladder cancer-the fifth study of the Japanese Urological Cancer Research Group for Adriamycin/Farumorubicin. Gan To Kagaku Ryoho. 29:73-80 (2002).
29. N. Gad el Mawla, M. A. Mansour, S. Eissa, N. M. Ali, I. Elattar, M. R. Hamza et al. A randomized pilot study of high-dose epirubicin as neoadjuvant chemotherapy in the treatment of cancer of the bilharzial bladder. Ann. Oncol. 2:137-140 (1991).
30. W. G. Jones, M. P. Sokal, M. J. Ostrowski, and D. W. Newling. A phase II study of epirubicin in advanced transitional cell bladder cancer. The Yorkshire Urological Cancer Research Group. Clin. Oncol. 5:25-29 (1993).
31. K. Nomata, M. Noguchi, H. Kanetake, N. Tsuda, M. Hayashi, S. Yamashita et al. Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: results of a randomized trial with epirubicin comparing short-term versus long-term maintenance treatment. Cancer Chemother. Pharmacol. 50:266-270 (2002).
32. B. Liu, Z. Wang, B. Chen, J. Yu, P. Zhang, Q. Ding et al. Randomized study of single instillation of epirubicin for superficial bladder carcinoma: long-term clinical outcomes. Cancer Invest. 24:160-163 (2006).
33. Y. Horn, A. Eidelman, N. Walach, E. Yuval, and A. Markowitz. Treatment of superficial bladder tumors in a controlled trial with thio-TEPA versus adriamycin. J. Surg. Oncol. 27:67-69 (1984).
34. J. A. Martínez-Piñeiro, J. Jiménez León, L. Martínez-Piñeiro Jr, L. Fiter, J. A. Mosteiro, J. Navarro et al. Bacillus Calmette-Guerin versus doxorubicin versus thiotepa: a randomized prospective study in 202 patients with superficial bladder cancer. J. Urol. 143:502-506 (1990).
35. J. Flamm, W. Kühnel, and S. Dona. Short-term versus long-term chemoprevention of recurrence with Epodyl following transurethral resection of superficial urinary bladder cancer. Urologe A. 28:99-102 (1989).
36. J. Flamm, G. Donner, A. Bucher, W. Holtl, W. Albrecht, and L. Havelec. Topical immunotherapy (KLH) vs. chemotherapy (Ethoglucid) in prevention of recurrence of superficial bladder cancer. A prospective randomized study. Urologe A. 33:138-143 (1994).
37. K. Kurth, U. Tunn, R. Ay, F. H. Schröder, M. Pavone-Macaluso, F. Debruyne et al. Adjuvant chemotherapy for superficial transitional cell bladder carcinoma: long-term results of a European Organization for Research and Treatment of Cancer randomized trial comparing doxorubicin, ethoglucid and transurethral resection alone. J. Urol. 158:378-384 (1997).
38. D. W Newling, J. Hetherington, S. K. Sundaram, M. R. Robinson, and L. Kisbenedek. The use of valrubicin for the chemoresection of superficial bladder cancer-a marker lesion study. Eur. Urol. 39:643-647 (2001).
39. A. L. Patterson, R. E. Greenberg, L. Weems, R. Bahnson, Z. Wajsman, M. Israel et al. Pilot study of the tolerability and toxicity of intravesical valrubicin immediately after transurethral resection of superficial bladder cancer. Urology. 56:232-235 (2000).
40. G. Steinberg, R. Bahnson, S. Brosman, R. Middleton, Z. Wajsman, and M. Wehle. Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group. J. Urol. 163:761-767 (2000).
41. S. D. Williams, L. H. Einhorn, and J. P. Donohue. cis-Platinum combination chemotherapy of bladder cancer: an update. Cancer Clin. Trials. 2:335-338 (1979).
42. J. A. Martinez-Piñeiro, M. Gonzalez Martin, F. Arocena, N. Flores, C. R. Roncero, J. A. Portillo et al. Neoadjuvant cisplatin chemotherapy before radical cystectomy in invasive transitional cell carcinoma of the bladder: a prospective randomized phase III study. J. Urol. 153:964-973 (1995).
43. N. K. Gogna, J. H. Matthews, S. L. Turner, H. Mameghan, G. M. Duchesne, N. Spry et al. Efficacy and tolerability of concurrent weekly low dose cisplatin during radiation treatment of localised muscle invasive bladder transitional cell carcinoma: a report of two sequential Phase II studies from the Trans Tasman Radiation Oncology Group. Radiother. Oncol. 81:9-17 (2006).
44. W. M. Stadler, T. Kuzel, B. Roth, D. Raghavan, and F. A. Dorr. Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer. J. Clin. Oncol. 15:3394-3398 (1997).
45. V. Lorusso, C. F. Pollera, M. Antimi, G. Luporini, C. Gridelli, G. L. Frassineti et al. A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer. Eur. J. Cancer. 34:1208-1212 (1998).
46. H. M. Khaled, M. R. Hamza, O. Mansour, R. Gaafar, and M. S. Zaghloul. A phase II study of gemcitabine plus cisplatin chemotherapy in advanced bilharzial bladder carcinoma. Eur. J. Cancer. 36(Suppl 2):34-37 (2000).
47. E. M. Uchio, W. M. Linehan, W. D. Figg, and M. M. Walther. A phase I study of intravesical suramin for the treatment of superficial transitional cell carcinoma of the bladder. J. Urol. 169:357-360 (2003).
48. J. J. Ord, E. Streeter, A. Jones, K. Le Monnier, D. Cranston, J. Crew et al. Phase I trial of intravesical Suramin in recurrent superficial transitional cell bladder carcinoma. Br. J. Cancer. 92:2140-2147 (2005).
49. P. A. Kosmidis, C. Bacoyiannis, and H. Hatzichristou. Combination chemotherapy with cis-platinum, adriamycin, mitomycin-C (PAM) in patients with advanced bladder cancer. J. Chemother. 2:397-400 (1990).
50. C. Sola, J. Mallafre, L. Mendoza Solorzano, A. Segarra, M. Daniels, N. Vinolas et al. Carboplatin, methotrexate, vinblastine and epirubicin (Carbo-MVE) for transitional cell bladder carcinoma. Ann. Oncol. 4:313-316 (1993).
51. W. K. Oh, J. Manola, J. P. Richie, K. R. Loughlin, and P. W. Kantoff. A phase II trial of methotrexate, cisplatin, 5-fluorouracil, and leucovorin in the treatment of invasive and metastatic urothelial carcinoma. Cancer. 86:1329-1334 (1999).
52. T. H. Ecke, P. Bartel, S. Koch, J. Ruttloff, and F. Theissig. Chemotherapy with gemcitabine, paclitaxel, and cisplatin in the treatment of patients with advanced transitional cell carcinoma of the urothelium. Oncol. Rep. 16:1381-1388 (2006).
53. S. B. Malkowicz. The role of intravesical chemotherapy in the treatment of bladder cancer. In S. P. Lerner, M. Schoenberg, and C. Sternberg (eds.), Textbook of Bladder Cancer, Informa Healthcare, London, 2006, pp. 335-340.
54. L. A. Pinke, and D. L. Lamm. Intravesical immunotherapy: BCG. In S. P. Lerner, M. Schoenberg, and C. Sternberg (eds.), Textbook of Bladder Cancer, Informa Healthcare, London, 2006, pp. 353-358.
55. A. Böhle, D. Jocham, and P. R. Bock. Intravesical Bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer. A formal meta-analysis of comparative studies on recurrence and toxicity. J. Urol. 169:90-95 (2003).
56. M. A. O'Donnell, J. Krohn, and W. C. DeWolf. Salvage intravesical therapy with interferon-alpha 2b plus low dose bacillus Calmette-Guerin is effective in patients with superficial bladder cancer in whom bacillus Calmette-Guerin alone previously failed. J. Urol. 166:1300-1304 (2001).
57. S. P. Punnen, J. L. Chin, and M. A. Jewett. Management of Bacillus Calmette-Guerin (BCG) refractory superficial bladder cancer: results with intravesical BCG and Interferon combination therapy. Can. J. Urol. 10:1790-1795 (2003).
58. J. S. Lam, M. C. Benson, M. A. O'Donnell, A. Sawczuk, A. Gavazzi, M. H. Wechsler et al. Bacillus Calmette-Guerin plus interferon-alpha2B intravesical therapy maintains an extended treatment plan for superficial bladder cancer with minimal toxicity. Urol. Oncol. 21:354-360 (2003).
59. F. N. Joudi, B. J. Smith, and M. A.O'Donnell. Final results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer. National BCG-Interferon Phase 2 Investigator Group, Urol. Oncol. 24:344-348 (2006).
60. G. Steinberg, R. Bahnson, S. Brosman, R. Middleton, Z. Wajsman, and M. Wehle. Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group. J. Urol. 163:761-767 (2000).
61. G. Dalbagni, P. Russo, B. Bochner, L. Ben-Porat, J. Sheinfeld, P. Sogani et al. Phase II trial of intravesical gemcitabine in Bacille Calmette-Guérin-Refractory transitional cell carcinoma of the bladder. J. Clin. Oncol. 24:2729-2734 (2006).
62. M. Gacci, R. Bartoletti, T. Cai, S. Nerozzi, N. Pinzi, F.Repetti, TUR (Toscana Urologia) Group et al. Intravesical gemcitabine in BCG-refractory T1G3 transitional cell carcinoma of the bladder: a pilot study. Urol. Int. 76:106-111 (2006).
63. M. G. Wientjes, R. A. Badalament, and J. L. Au. Use of pharmacologic data and computer simulations to design an efficacy trial of intravesical mitomycin C therapy for superficial bladder cancer. Cancer Chemother. Pharmacol. 32:255-262 (1993).
64. W. J. Underberg, and H. Lingeman. Aspects of the chemical stability of mitomycin and porfiromycin in acidic solution. J. Pharm. Sci. 72:549-553 (1983).
65. J. H. Beijnen, H. Lingeman, H. A. Van Munster, and W. J. Underberg. Mitomycin antitumor agents: a review of their physicochemical and analytical properties and stability. J. Pharm. Bio. Anal. 4:275-295 (1986).
66. B. E. Cohen, M. J. Egorin, M. S. Nayar, and P. L. Gutierrez. Effects of pH and temperature on the stability and decomposition of N,N'N''- triethylenethiophosphoramide in urine and buffer. Cancer Res. 44:4312-4316 (1984).
67. J. B. Mellett, and L. A. Woods. The comparative physiological disposition of thiotepa and tepa in the dog. Cancer Res. 20:524-532 (1960).
68. K. F. Ilett, R. T. Ong, K. T. Batty, and J. D. Taylor. Effect of urine pH on the stability of doxorubicin and its recovery from bladder instillations. Br. J. Urol. 65:478-482 (1990).
69. W. C. Yen, T. Schmittgen, and J. L. Au. Different pH dependency of mitomycin C activity in monolayer and three-dimensional cultures. Pharm. Res. 13:1887-1891 (1996).
70. N. M. Harris, P. M. Duffy, T. J. Crook, W. R. Anderson, P. Sharpe, M. C. Hayes et al. Intravesical pH: a potentially important variable affecting efficacy and the further development of anthracycline chemotherapy for superficial bladder cancer. BJU Int. 90:957-964 (2002).
71. A. M. Cliff, B. Heatherwick, J. Scoble, and N. J. Parr. The effect of fasting or desmopressin before treatment on the concentration of mitomycin C during intravesical administration. BJU Int. 86:644-647 (2000).
72. M. G. Wientjes, R. A. Badalament, R. C. Wang, F. Hassan, and J. L. Au. Penetration of mitomycin C in human bladder. Cancer Res. 53:3314-3320 (1993).
73. D. Song, M. G. Wientjes, Y. Gan, and J. L. Au. Bladder tissue pharmacokinetics and antitumor effect of intravesical 5-fluorouridine. Clin. Cancer Res. 3:901-909 (1997).
74. M. G. Wientjes, R. A. Badalament, and J. L. Au. Penetration of intravesical doxorubicin in human bladders. Cancer Chemother. Pharmacol. 37:539-546 (1996).
75. M. Pavone-Macaluso, N. Gebbia, F. Biondo, S. Bertolini, G. Caramia, and F. P. Rizzo. Permeability of the bladder mucosa to thiotepa, adriamycin, and daunomycin in men and rabbits. Urol. Res. 4:9-13 (1976).
76. G. Lunglmayr, and K. Czech. Absorption studies on intraluminal thio-tepa for topical cytostatic treatment of low-stage bladder tumors. J. Urol. 106:72-74 (1971).
77. I. Grabnar, M. Bogataj, A. Belic, V. Logar, R. Karba, and A. Mrhar. Kinetic model of drug distribution in the urinary bladder wall following intravesical instillation. Int. J. Pharm. 322:52-59 (2006).
78. J. L. Au, R. A. Badalament, M. G. Wientjes, D. C. Young, J. A. Warner, P. L. Venema et al. Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial. J. Natl. Cancer Inst. 93:597-604 (2001).
79. G. R. Sant. Intravesical 50% dimethyl sulfoxide (Rimso-50) in treatment of interstitial cystitis. Urology. 29(Suppl 4):17-21 (1987).
80. R. H. Schoenfeld, W. D. Belville, W. H. Jacob, A. S. Buck, M. L. Dresner, S. J. Insalaco et al. The effect of dimethyl sulfoxide on the uptake of cisplatin from the urinary bladder of the dog: a pilot study. J. Am. Osteopath. Assoc. 82:570-573 (1983).
81. H. Hashimoto, S. Tokunaka, M. Sasaki, M. Nishihara, and S. Yachiku. Dimethylsulfoxide enhances the absorption of chemotherapeutic drug instilled into the bladder. Urol. Res. 20:233-236 (1992).
82. W. A. See, and Q. Xia. Regional chemotherapy for bladder neoplasms using continuous intravesical infusion of doxorubicin: impact of concomitant administration of dimethyl sulfoxide on drug absorption and antitumor activity. J. Natl. Cancer Inst. 84:510-515 (1992).
83. D. Chen, D. Song, M. G. Wientjes, and J. L. Au. Effect of dimethyl sulfoxide on bladder tissue penetration of intravesical paclitaxel. Clin. Cancer Res. 9:363-369 (2003).
84. M. K. Kos, M. Bogataj, P. Veranic, and A. Mrhar. Permeability of pig urinary bladder wall: time and concentration dependent effect of chitosan. Biol. Pharm. Bull. 29:1685-1691 (2006).
85. I. Grabnar, M. Bogataj, and A. Mrhar. Influence of chitosan and polycarbophil on permeation of a model hydrophilic drug into the urinary bladder wall. Int. J. Pharm. 256:167-173 (2003).
86. B. D. Kuppermann, E. L. Thomas, M. D. de Smet, and L. R. Grillone. Vitrase for Vitreous Hemorrhage Study Groups. Safety results of two phase III trials of an intravitreous injection of highly purified ovine hyaluronidase (Vitrase) for the management of vitreous hemorrhage. Am. J. Ophthalmol. 140:585-597 (2005).
87. (No authors listed). Hyaluronidase (Vitrase)-ISTA: hyaluronidase-ISTA pharmaceuticals. Drugs R&D. 4:194-97 (2003).
88. M. Sasaki, H. Hashimoto, and S. Yachiku. Studies on enhancement of drug absorption through the bladder mucosa. Nippon Hinyokika Gakkai Zasshi. 85:1353-1362 (1994).
89. Y. Horn, A. Eidelman, N. Walach, M. Waron, and F. Barak. Intravesical chemotherapy of superficial bladder tumors in a controlled trial with cis-platinum versus cis-platinum plus hyaluronidase. J. Surg. Oncol. 28:304-307 (1985).
90. U. Maier, and G. Baumgartner. Mitomycin C plasma levels after intravesical instillation with and without hyaluronidase. J. Urol. 135:845-846 (1986).
91. K. Hobarth, U. Maier, and M. Marberger. Topical chemoprophylaxis of superficial bladder cancer with mitomycin C and adjuvant hyaluronidase. Eur. Urol. 21:206-210 (1992).
92. V. B. Lokeshwar, W. H. Cerwinka, and B. L. Lokeshwar. HYAL1 hyaluronidase: a molecular determinant of bladder tumor growth and invasion. Cancer Res. 65:2243-2250 (2005).
93. V. B. Lokeshwar, V. Estrella, L. Lopez, M. Kramer, P. Gomez, M. S. Soloway et al. HYAL1-v1, an alternatively spliced variant of HYAL1 hyaluronidase: a negative regulator of bladder cancer. Cancer Res. 66:11219-11227 (2006).
94. S. M. Di Stasi, G. Vespasiani, A. Giannantoni, R. Massoud, S. Dolci, and F. Micali. Electromotive delivery of mitomycin C into human bladder wall. Cancer Res. 57:875-880 (1997).
95. S. M. Di Stasi, A. Giannantoni, R. Massoud, S. Dolci, P. Navarra, G. Vespasiani et al. Electromotive versus passive diffusion of mitomycin C into human bladder wall: concentration-depth profiles studies. Cancer Res. 59:4912-4918 (1999).
96. M. Brausi, B. Campo, G. Pizzocaro, P. Rigatti, A. Parma, G. Mazza et al. Intravesical electromotive administration of drugs for treatment of superficial bladder cancer: A comparative phase II study. Urology. 51:506-509 (1998).
97. S. M. Di Stasi, A. Giannantoni, R. L. Stephen, G. Capelli, P. Navarra, R. Massoud et al. Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study. J. Urol. 170:777-782 (2003).
98. S. M. Di Stasi, A. Giannantoni, A. Giurioli, M. Valenti, G. Zampa, L. Storti et al. Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial. Lancet Oncol. 7:43-51 (2006).
99. E. Rintala, K. Jauhiainen, P. Rajala, M. Ruutu, E. Kaasinen, O. Alfthan et al. Alternating mitomycin-C and bacillus calmette-guerin instillation therapy for carcinoma in situ of the bladder. J. Urol. 154:2050-2053 (1995).
100. E. Rintala, K. Jauhiainen, E. Kaasinen, M. Nurmi, and O. Alfthan. Alternating mitomycin-C and bacillus calmette-guerin instillation prophylaxis for recurrent papillary (stages Ta-T1) superficial bladder cancer. J. Urol. 156:56-59 (1996).
101. J. A. Witjes, C. T. Caris, N. A. Mungan, F. M. Debruyne, and W. P. Witjes. Results of a randomised phase III trial of sequential intravesical therapy with mitomycin-C and bacillus calmette-guerin vs mitomycin-C alone in patients with superficial bladder cancer. J. Urol. 160:1668-1671 (1998).
102. E. Kaasinen, H. Wijkström, P. U. Malmström, S. Hellsten, M. Duchek, O. Mestad et al. Nordic Urothelial Cancer Group. Alternating mitomycin C and BCG instillations versus BCG alone in treatment of carcinoma in situ of the urinary bladder: a Nordic study. Eur. Urol. 43:637-645 (2003).
103. P. M. Corry, S. Robinson, and S. Getz. Hyperthermic effects on DNA repair mechanisms. Radiology. 123:475-482 (1977).
104. T. S. Herman, B. A. Teicher, M. Jochelson, J. Clark, G. Svensson, and C. N. Coleman. Rationale for use of local hyperthermia with radiation therapy and selected anticancer drugs in locally advanced human malignancies. Int. J. Hypertherm. 4:143-158 (1988).
105. B. Moskovitz, M. G. eyer, A. Kravtzov, M. Gross, A. Kastin, K. Biton et al. Thermo-chemotherapy for intermediate or high-risk recurrent superficial bladder cancer patients. Ann. Oncol. 16:585-589 (2005).
106. A. G. van der Heijden, L. A. Kiemeney, O. N. Gofrit, O. Nativ, A. Sidi, Z. Leib et al. Preliminary European results of local microwave hyperthermia and chemotherapy treatment in intermediate or high risk superficial transitional cell carcinoma of the bladder. Eur. Urol. 46:65-71 (2004).
107. C. Le Visage, N. Rioux-Leclercq, M. Haller, P. Breton, B. Malavaud, and K. Leong. Efficacy of paclitaxel released from bio-adhesive polymer microspheres on model superficial bladder cancer. J. Urol. 171:1324-1329 (2004).
108. P. Tyagi, Z. Li, M. Chancellor, W. C. De Groat, N. Yoshimura, and L. Huang. Sustained intravesical drug delivery using thermosensitive hydrogel. Pharm. Res. 21:832-837 (2004).
109. Z. Ye, J. Chen, X. Zhang, J. Li, S. Zhou, W. Yang et al. Novel gelatin-adriamycin sustained drug release system for intravesical therapy of bladder cancer. J. Tongji Med. Univ. 21:145-148 (2001).
110. T. Leakakos, C. Ji, G. Lawson, C. Peterson, and S. Goodwin. Intravesical administration of doxorubicin to swine bladder using magnetically targeted carriers. Cancer Chemother. Pharmacol. 51:445-450 (2003).
111. R. C. Bast Jr, and G. B. Mills. In J. M. S. Bartlett (ed.), Ovarian Cancer: Methods and Protocols, Humana Press, New Jersey, 2000, pp. 37-48.
112. I. Fodor, T. Timiryasova, B. Denes, J. Yoshida, H. Ruckle, and M. Lilly. Vaccinia virus mediated p53 gene therapy for bladder cancer in an orthotopic murine model. J. Urol. 173:604-609 (2005).
113. J. M. Bergelson, J. A. Cunningham, G. Droguett, E. A. Kurt-Jones, A. Krithivas, J. S. Hong et al. Isolation of a common receptor for coxsackie b viruses and adenoviruses 2 and 5. Science. 275:1320-1323 (1997).
114. R. P. Tomko, R. Xu, and L. Philipson. HCAR and MCAR, the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackie viruses. Proc. Natl. Acad. Sci. U. S. A. 94:3352-3356 (1997).
115. J. D. Lilly, and C. L. Parsons. Bladder surface glycosaminoglycans is a human epithelial permeability barrier. Surg. Gynecol. Obstet. 171:493-496 (1990).
116. J. C. Nickel, J. Downey, A. Morales, L. Emerson, and J. Clark. Relative efficacy of various exogenous glycosaminoglycans in providing a bladder surface permeability barrier. J. Urol. 160:612-614 (1998).
117. H. Engler, S. C. Anderson, T. R. Machemer, J. M. Philopena, R. J. Connor, S. F. Wen et al. Ethanol improves adenovirus-mediated gene transfer and expression to the bladder epithelium of rodents. Urology. 53:1049-1053 (1999).
118. N. Ramesh, B. Memarzadeh, Y. Ge, D. Frey, M. VanRoey, V. Rojas et al. Identification of pretreatment agents to enhance adenovirus infection of bladder epithelium. Mol. Ther. 10:697-705 (2004).
119. R. J. Connor, H. Engler, T. Machemer, J. M. Philopena, M. T. Horn, S. Sutjipto et al. Identification of polyamides that enhance adenovirus-mediated gene expression in the urothelium. Gene Ther. 8:41-48 (2001).
120. L. F. Lin, G. Zhu, J. J. Yoo, S. Soker, V. P. Sukhatme, and A. Atala. A system for the enhancement of adenovirus mediated gene transfer to uro-epithelium. J. Urol. 168:813-818 (2002).
121. R. J. Connor, J. M. Anderson, T. Machemer, D. C. Maneval, and H. Engler. Sustained intravesical interferon protein exposure is achieved using an adenoviral-mediated gene delivery system: a study in rats evaluating dosing regimens. Urology. 66:224-229 (2005).
122. Z. Tao, R. J. Connor, F. Ashoori, C. P. Dinney, M. Munsell, J. A. Philopena et al. Efficacy of a single intravesical treatment with Ad-IFN/Syn 3 is dependent on dose and urine IFN concentration obtained: implications for clinical investigation. Cancer Gene Ther. 13:125-130 (2006).
123. P. E. Werthman, K. E. Drazan, J. T. Rosenthal, R. Khalili, and A. Shaked. Adenoviral-p53 gene transfer to orthotopic and peritoneal murine bladder cancer. J. Urol. 155:753-756 (1996).
124. K. Inoue, P. Perrotte, C. G. Wood, J. W. Slaton, P. Sweeney, and C. P. Dinney. Gene therapy of human bladder cancer with adenovirus-mediated antisense basic fibroblast growth factor. Clin. Cancer Res. 6:4422-4431 (2000).
125. K. Inoue, C. G. Wood, J. W. Slaton, T. Karashima, P. Sweeney, and C. P. Dinney. Adenoviral-mediated gene therapy of human bladder cancer with antisense interleukin-8. Oncol. Rep. 8:955-964 (2001).
126. N. Ramesh, Y. Ge, D. L. Ennist, M. Zhu, M. Mina, S. Ganesh et al. CG0070, a conditionally replicating granulocyte macrophage colony-stimulating factor-armed oncolytic adenovirus for the treatment of bladder cancer. Clin. Cancer Res. 12:305-313 (2006).
127. Dose-escalation study of CG0070 for bladder cancer after BCG (Bacillus Calmette-Guerin) Failure. (NCI clinical trial protocol # V-0046, NCT00109655).
128. B. Moss. Reproduction of poxviruses. In H. Frankel-Conrat (ed.), Comprehensive Virology, 3, Plenum Press, New York, 1974, pp. 405-474.
129. S. S. Lee, L. C. Eisenlohr, P. A. McCue, M. J. Mastrangelo, and E. C. Lattime. Intravesical gene therapy: in vivo gene transfer using recombinant vaccinia virus vectors. Cancer Res. 54:3325-3328 (1994).
130. L. G. Gomella, M. J. Mastrangelo, P. A. McCue, H. C. Maguire Jr, S. G. Mulholland, and E. C. Lattime. Phase I study of intravesical vaccinia virus as a vector for gene therapy of bladder cancer. J. Urol. 166:1291-1295 (2001).
131. J. Kuball, S. F. Wen, J. Leissner, D. Atkins, P. Meinhardt, E. Quijano et al. Successful adenovirus-mediated wild-type p53 gene transfer in patients with bladder cancer by intravesical vector instillation. J. Clin. Oncol. 20:957-965 (2002).
132. L. C. Pagliaro, A. Keyhani, D. Williams, D. Woods, B. Liu, P. Perrotte et al. Repeated intravesical instillations of an adenoviral vector in patients with locally advanced bladder cancer: a phase I study of p53 gene therapy. J. Clin. Oncol. 21:2247-2253 (2003).
133. A phase I study of the safety and tolerability of intravesical administration of SCH 721015 in patients with transitional cell carcinoma of the bladder. MD Anderson cancer center. Clinical trial # 2005-0580.
134. S. Li, and L. Huang. Nonviral gene therapy: promises and challenges. Gene Ther. 7:31-34 (2000).
135. Y. Horiguchi, W. A. Larchian, R. Kaplinsky, W. R. Fair, and W. D. Heston. Intravesical liposome-mediated interleukin-2 gene therapy in orthotopic murine bladder cancer model. Gene Ther. 7:844-851 (2000).
136. M. Horinaga, K. M. Harsch, R. Fukuyama, W. Heston, and W. Larchian. Intravesical interleukin-12 gene therapy in an orthotopic bladder cancer model. Urology. 66:461-466 (2005).
137. Y. Liao, Y.Y. Zou, W.Y. Xia, and M.C. Hung. Enhanced paclitaxel cytotoxicity and prolonged animal survival rate by a nonviral-mediated systemic delivery of E1A gene in orthotopic xenograft human breast cancer. Cancer Gene Ther. 11:594-602 (2004).
138. S. Liu, X. P. Wang, and F. C. Brunicardi. Enhanced cytotoxicity of RIPTK gene therapy of pancreatic cancer via PDX-1 co-delivery. J. Surg. Res. 137:1-9 (2007).
139. P. F. Chen, G. F. Fu, H. Y. Zhang, G. X. Xu, and Y. Y. Hou. Liposomal plasmid DNA encoding human thymosin alpha and interferon omega potently inhibits liver tumor growth in ICR mice. J. Gastroenterol. Hepatol. 21:1538-1543 (2006).
140. S. Fletcher, A. Ahmad, E. Perouzel, A. Heron, A. D. Miller, and M. R. Jorgensen. In vivo studies of dialkynoyl analogues of DOTAP demonstrate improved gene transfer efficiency of cationic liposomes in mouse lung. J. Med. Chem. 49:349-357 (2006).
141. E. W. Alton, M. Stern, R. Farley, A. Jaffe, S. L. Chadwick, J. Phillips et al. Cationic lipid-mediated CFTR gene transfer to the lungs and nose of patients with cystic fibrosis: a double-blind placebo-controlled trial. Lancet. 353:947-954 (1999).
142. S. Dow, R. Elmslie, I. Kurzman, G. MacEwen, F. Pericle, and D. Liggitt. Phase I study of liposome-DNA complexes encoding the interleukin-2 gene in dogs with osteosarcoma lung metastases. Hum. Gene Ther. 16:937-946 (2005).
143. C. M. Rudin, J. L. Marshall, C. H. Huang, H. L. Kindler, C. Zhang, D. Kumar et al. Delivery of a liposomal c-raf-1 antisense oligonucleotide by weekly bolus dosing in patients with advanced solid tumors: a phase I study. Clin. Cancer Res. 10:7244-7251 (2004).
144. H. Xia, Q. Mao, H. L. Paulson, and B. L. Davidson. siRNA-mediated gene silencing in vitro and in vivo. Nat. Biotechnol. 20:1006-1010 (2002).
145. U. N. Verma, R. M. Surabhi, A. Schmaltieg, C. Becerra, and R. B. Gaynor. Small interfering RNAs directed against ß-Catenin inhibit the in vitro and in vivo growth of colon cancer cells. Clin Cancer Res. 9:1291-1300 (2003).
146. R. M. Schiffelers, A. Ansari, J. Xu, Q. Zhou, Q. Tang, G. Storm et al. Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res. 32:e149 (2004).
147. S. Ning, S. Fuessel, M. Kotzsch, K. Kraemer, M. Kappler, U. Schmidt et
148. J. Q. Hou, J. He, X. L. Wang, D. G. Wen, and Z. X. Chen. Effect of small interfering RNA targeting survivin gene on biological behaviour of bladder cancer. Chin. Med. J. 119:1734-1739 (2006).
149. L. Zou, P. Zhang, C. Luo, and Z. Tu. shRNA-targeted hTERT suppress cell proliferation of bladder cancer by inhibiting telomerase activity. Cancer Chemother. Pharmacol. 57:328-334 (2006).
150. M. Nogawa, T. Yuasa, S. Kimura, M. Tanaka, J. Kuroda, K. Sato et al. Intravesical administration of small interfering RNA targeting PLK-1 successfully prevents the growth of bladder cancer. Clin. Invest. 115:978-985 (2005).
151. S. J. Mackie, D. M. Sharma, A. J. Cooper, N. M. Harris, B. A. Lwaleed et al. Meglumine Eicosapentaenoic acid (MeEPA) a new soluble omega-3 fatty acid formulation: in vitro bladder cancer cytotoxicity tests in combination with epirubicin and mitomycin. Prostaglandins. 75:367-373 (2006).
152. Y. Xin, G. Lyness, D. Chen, S. Song, M. G. Wientjes, and J. L. Au. Low dose suramin as a chemosensitizer of bladder cancer to mitomycin C. J. Urol. 174:322-327 (2005).
153. S. H. Song, M. G. Wientjes, Y. B. Gan, and J. L. Au. Fibroblast growth factors: an epigenetic mechanism of broad spectrum resistance to anticancer drugs. Proc. Natl. Acad. Sci. U. S. A. 97:8658-8663 (2000).
154. P. Nygren, and R. Larsson. Overview of the clinical efficacy of investigational anticancer drugs. J. Intern. Med. 253:46-75 (2003).